1-877-YALEMDS
Ophthalmic Oncology
The Ocular Oncology Section is led by Dr. Miguel A. Materin. Ocular tumors can be benign or malignant. Malignant tumors of the eye are life-threatening conditions affecting patients without distinction of age, gender or race.
The goal of the Ocular Oncology Section at Yale is to improve the prognosis of these rare diseases in terms of life, conservation of the eye and sight.
Special services offered by this program include:
- Benign tumors (like choroidal nevus, choroidal hemangiomas)
- Pseudotumors
- Malignant melanoma (iris, ciliary body, choroid, conjunctiva, eyelid, orbit and metastatic melanoma to the eye)
- Retinoblastoma (most common intraocular malignancy in children)
- Ocular metastasis from systemic cancers
- Retinal tumors (retinal hemangioblastomas also known as retinal capillary hemangiomas, and other vascular tumors, astrocytic tumors, adenomas and adenocarcinomas of the retinal pigment epithelium, and others)
- Conjunctival tumors
- von Hippel Lindau disease, Neurofibromatosis, Sturge Weber syndrome
|
Materin, Miguel A, MD | Associate Professor of Ophthalmology and Visual Science; Director of Ophthalmic Oncology | (203) 785-2020 Appts
(203) 737-2181 Fax |
